טוען...
The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis
Vedolizumab, an α4β7-integrin antagonist, is the first gut-selective monoclonal antibody that has been approved for the treatment of moderate-to-severe ulcerative colitis and Crohn’s disease in many countries in the world. However, questions still remain regarding its appropriate use and placement i...
שמור ב:
| הוצא לאור ב: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4830105/ https://ncbi.nlm.nih.gov/pubmed/27134663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16635081 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|